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1748-6815/ª 2016 British Association ofSummary Background: Reduction mammaplasty is one of the most common plastic surgery
procedures. Preoperative imaging and histopathology protocols vary among countries and in-
stitutions.
We aimed to analyze the incidence of occult breast cancer and high-risk lesions in reduction
mammaplasty specimens. We also analyzed whether patients with abnormal histopathology
differed from the study population in terms of demographics.
Patients and methods: In total, 918 women who underwent reduction mammaplasty from
January 2007 to December 2011 were retrospectively reviewed for demographics, preoperative
imaging, further preoperative examinations, pathology reports, and postoperative follow-up.
Results: Abnormal histopathological findings were revealed in 88 (10%) patients with a mean
age of 49.5  10.2 years. The incidence of breast cancer was 1.2%, and the incidence of
high-risk lesions (atypical ductal and lobular hyperplasia and lobular carcinoma in situ) was
5.5%. Age and specimen weights were significantly higher in patients with abnormal histopa-
thology. Eighty-one percent of patients with abnormal histopathology had normal preoperative
imaging revealing two high-risk and two cancer findings. Two patients developed breast cancer
in the same breast in which the high-risk lesion was originally detected.
Conclusion: Women with abnormal histopathology cannot be sufficiently detected preopera-
tively. Therefore, histopathological analysis of reduction mammaplasty specimens seemsUppsala, Congress of the Scandinavian Association of Plastic Surgeons, on 16 June 2016.
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Should we routinely analyze reduction mammaplasty specimens? 197mandatory. Reduction mammaplasty combined with subsequent histopathological examination
offers a sufficient chance of detecting cancer and risk-increasing lesions that merits the cost of
histopathology.
ª 2016 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Else-
vier Ltd. All rights reserved.Introduction
Reduction mammaplasty involves many breast and plastic
surgeons. Common indications for the surgery are symp-
tomatic macromastia, breast asymmetry, and contralateral
symmetrization during or after breast cancer surgery.
Despite preoperative evaluation and examination of the
patients, occult breast cancer and benign breast disease
demonstrating increased risk of breast cancer may appear
in reduction mammaplasty specimens.
The incidence of occult breast cancer in reduction
mammaplasty specimens has been studied in several
countries, with incidence ranging from 0.05% to 4.5%.1e16
However, comparison between studies is made difficult
because of variations in study methodologies and definition
of relevant breast pathology findings. Moreover, inclusion
of in situ findings or patients with previous history of breast
cancer produce discrepancies.1
Women with benign breast disease, typically found in
reduction mammaplasty specimens,2,3,8,12,13,15,17e19 are at
a higher risk of breast cancer.20e31 Proliferative breast le-
sions without atypia cause slightly increased risk (1.5e2.0
times), atypical ductal hyperplasia (ADH) and atypical
lobular hyperplasia (ALH) cause moderately increased risk
(4.0e5.0 times), and ductal carcinoma in situ (DCIS) and
lobular carcinoma in situ (LCIS) markedly increased the risk
(8.0e10.0 times) of breast cancer.25
The aim of our study was to analyze the incidence of
occult breast cancer and findings demonstrating increased
risk of breast cancer in reduction mammaplasty specimens.
We also analyzed whether patients with abnormal histo-
pathology differed from those with normal histopathology
in terms of demographics.Table 1 BI-RADS classification.
Category Definition Likelihood of cancer
BI-RADS 0 Incomplete N/A
BI-RADS 1 Negative Essentially 0%
BI-RADS 2 Benign Essentially 0%
BI-RADS 3 Probably benign >0%, but 2%
BI-RADS 4 Suspicious >2%, but <95%
BI-RADS 5 Highly suggestive
of malignancy
95%
BI-RADS 6 Known biopsy-proven
malignancy
N/A
Adopted from ACR BI-RADS Atlas, Breast Imaging Reporting and
Data System.Patients and methods
Patients who underwent reduction mammaplasty in the
Department of Plastic and Reconstructive surgery, Helsinki
University Hospital, between January 2007 and December
2011 were reviewed. Postoperative surveillance of the pa-
tients with abnormal histopathology until October 2015 was
included. The study was approved by the University Hos-
pital Research Board.
A total of 1255 women underwent reduction mamma-
plasties during the study period. Women with previous
history of breast cancer were excluded, and the final study
population was 918 women. The indications for the surgery
were symptomatic macromastia and asymmetry of the
breasts. One patient had undergone mastectomy because
of burn injury, and reduction mammaplasty was performedfor achieving better symmetry. Eleven patients entered the
study twice and one patient entered thrice because of re-
reductions. Unilateral procedures were performed in 35
cases because of congenital or postoperative asymmetry.
Findings were recorded per treated patient and not per
breast. Patient records were retrieved and retrospectively
analyzed for demographic data, preoperative imaging,
operative and histopathology reports, and postoperative
follow-up.
Preoperative imaging findings were classified according
to the American College of Radiology Breast Imaging
Reporting and Data System,32 as listed in Table 1.
Experienced pathologists performed the histopatholog-
ical evaluation of reduction mammaplasty specimens. After
fixing with formalin, the specimens were weighed and
examined. The specimens were cut into 1-cm slices that
were palpated for masses and areas of increased density.
Samples for tissue blocks were obtained from macroscopi-
cally suspicious areas and were evaluated histopathologi-
cally. The number of tissue blocks per breast varied
between four and 20, five being the most usual number.
Histopathological findings in reduction mammaplasty
specimens were categorized according to a consensus
statement outlined by the Cancer Committee of the College
of American Pathologists.25 In short, abnormal histopatho-
logical findings in our study included proliferative breast
lesions without atypia, ADH, ALH, LCIS, DCIS, and invasive
cancer. High-risk lesions included ADH, ALH, and LCIS.
Invasive cancer and DCIS were categorized as cancer find-
ings because of their similar clinical management. All other
histopathological findings were defined as normal breast
tissue. In 69 patients, no sample was obtained for histo-
pathology. The percentages of abnormal findings were
calculated from the number of samples available (nZ 849).





n Z 761 n Z 88
Mean agea 44.0  12.9 49.5  10.2





Smoking Yes: 88 (12%) Yes: 7 (8.0%)







1136.6  627.7 1331.2  581.7
Pluseminus values are means  SD.
a There is a statistical difference in age (p < 0.001) and
specimen weights (p < 0.001) between patients with abnormal
and normal histopathology.
b Five most common medical conditions: hypertension,
asthma, depression or depressed mood, hypercholesterolemia,
and hypothyroidism.
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(SD). Pearson’s chi-square test was applied in bivariate
analyses with categorical variables. ManneWhitney U test
was applied for difference in medians. P-values of <0.05
were considered statistically significant.
Results
A total of 918 women underwent reduction mammaplasty.
Flowchart 1 illustrates the samples that were available and
studied. In 69 (7.5%) patients, with a mean age of
40.6  12.7 years, no sample was obtained for histopath-
ological analysis. Histopathological evaluation of reduction
mammaplasty specimens revealed abnormal findings in 88
(10%) patients and normal breast tissue in 761 (90%) pa-
tients. The mean age (SD), body mass index, reduction
mammaplasty specimen weight, past medical history, pre-
vious breast surgery, and smoking habits of the patients
with normal and abnormal histopathology are listed in
Table 2. There was a statistically significant difference in
age (p < 0.001) and specimen weights (p < 0.001) between
patients with abnormal and normal histopathologies such
that abnormal histopathology correlated with a higher age
and heavier specimen.
Preoperative imaging
Preoperative imaging had been conducted in 89% of the
patients. There were 12 patients in whom preoperative
imaging was not conducted and the histopathological
analysis of reduction mammaplasty specimen was not
performed.
In patients with abnormal histopathology, preoperative
imaging was normal in 81% and suspicious of malignancy in
19% of the patients. Preoperatively two of 10 patients with
cancer findings and two of 47 patients with high-risk lesions
were detected.Flowchart Illustration of samples available and studied.Abnormal histopathology
Abnormal histopathological findings were revealed in 88
(10%) patients with a mean age of 49.5  10.2 years. In-
cidences of abnormal findings are presented in Table 3. Two
simultaneous abnormal findings were revealed in nine pa-
tients, three simultaneous abnormal findings were revealed
in one patient, and four simultaneous abnormal findings
were revealed in two patients.
High-risk lesions (ADH, ALH, and LCIS) were identified in
47 (5.5%) patients and also in two patients along with
cancer. In the subgroup of invasive cancer and DCIS, we
could identify 10 (1.2%) patients. The mean age of these
patients was 55.5  6.6 years. Two patients were simulta-
neously identified with DCIS and lobular cancer.
The incidence of abnormal histopathological findings by
age is presented in Table 4. A closer look at young women,
<30 years of age, revealed one patient (27 years) with ADH
finding. Similarly, among patients with age 30e40 years,Table 3 Abnormal histopathological diagnosis.
Diagnosis Number of patients %
Sclerosing adenosis 20 2.4%
Intraductal papilloma 19 2.2%





Carcinoma ductale 4 0.5%
Carcinoma lobulare 2 0.2%
Two simultaneous abnormal findings were revealed in nine pa-
tients, three simultaneous abnormal findings were revealed in
one patient, and four simultaneous abnormal findings were
revealed in two patients.






















Low-risk lesionb 11 15 7 4 37
(3.8%) (6.3%) (3.3%) (3.6%) (4.4%)
High-risk lesionc 5 12 19 11 47
(1.7%) (5.0%) (9.1%) (9.8%) (5.5%)
Cancerd 0 2 5 3 10
(0.0%) (0.8%) (2.4%) (2.7%) (1.2%)
Abnormal histopathological findings in total (p < 0.001) and high-risk lesions (p < 0.001) and cancer findings (p Z 0.003) were more
frequent with increasing age.
a Two simultaneous abnormal findings were revealed in nine patients, three simultaneous abnormal findings were revealed in one
patient, and four simultaneous abnormal findings were revealed in two patients.
b Sclerosing adenosis, intraductal papilloma, phylloid tumor.
c ADH, ALH, and LCIS.
d Invasive cancer and DCIS.
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pathological findings in total (p < 0.001) and high-risk le-
sions (p < 0.001) and cancer findings (pZ 0.003) were more
frequent with increasing age as shown in Table 4. However,
in the subgroup of patients with high-risk lesions, 36% were
<50 years of age.
In cases with abnormal postoperative histopathology,
family history of breast cancer was positive in 12 patients
and negative in 17 patients. The family history was not
available for 59 (67%) patients.
Postoperative surveillance
The mean follow-up period for patients with abnormal
histopathology and patients with no histopathological
analysis was 6.2  1.4 years. In our study, two patients
developed breast cancer on the same breast in which the
high-risk lesion was revealed in the reduction mammaplasty
specimen (Table 5). Active surveillance with bothTable 5 Patients with subsequent cancer.
Patient 1
Age at reduction mammaplasty 55
Preoperative imaging MMGa þ USb BI-RADS 2
Histopathology of the specimen ADH
Postoperative surveillance MMG þ US every 2 years
Cancer diagnosis method Screening MMG
Time of cancer diagnosis 4 years, 10 months
Treatment Mastectomy þ SNBc þ axillary
clearance, hormone therapy
Type of cancer Carcinoma ductale bifocale, g
pT1 (20 þ 2 mm), pN0 (iþ)
TNM classification of malignant tumors, 7th edition. Wiley Blackwell,
a MMG: Mammogram.
b US: Ultrasound.
c SNB: Sentinel node biopsy.mammogram and ultrasound every 2 years was recom-
mended for the majority of the patients with high-risk le-
sions (ADH, ALH, and LCIS). For 12 patients, information
about surveillance could not be found.
In 69 patients without histopathological analysis, pre-
operative imaging had been conducted for 57 (82.6%) pa-
tients, all with normal result. Retrospective survey of
patient records showed no indication of future oncological
treatment.Discussion
Reduction mammaplasty continues to be a common pro-
cedure in plastic and breast surgery. Despite thorough
preoperative evaluation and imaging, occult breast cancer
and findings demonstrating increased risk of breast cancer
are revealed in the specimens. We detected a considerable
number (10%) of abnormal findings in patients whoPatient 2
58
MMG þ US BI-RADS 2
LCIS
Recommended: screening MMG
Realized: symptomatic liponecrosis / annual
imaging and several biopsies
Skin biopsy
6 years, 8 months
Mastectomy, axillary clearance, preoperative
neoadjuvant chemotherapy, postoperative
radiotherapy, and hormone therapy
r I, Carcinoma lobulare bifocale, gr I, pT2 (30 þ 15 mm),
pN3a (14/21)
Oxford UK 2009.
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studies, the incidence of invasive carcinoma and DCIS varies
between 0.05% and 2.5%.1e16 In our study, the incidence of
breast cancer was 1.2%, which corresponds to that in pre-
vious studies.
Benign breast disease is an important predictor of future
breast cancer risk.20e31 Hartmann et al.31 showed that the
cumulative incidence of breast cancer at 25 years was 29%
in women with ADH or ALH. Similarly, King et al.28 showed a
2% annual incidence of breast cancer among women with
LCIS and an overall cumulative cancer incidence of 26% at
15 years. Coopey et al.30 showed an estimated 10 year
cancer risk with ADH, ALH, and LCIS at 17%, 21%, and 24%,
respectively. In our study, we detected high-risk lesions in
5.5% of the patients distributed across all age groups.
Therefore, reduction mammaplasty reveals a group of
women with marked and persistent elevation in breast
cancer risk.
In our study population, 11% of the patients with high-
risk lesions were <40 years of age, the youngest being 27
years old. Hassan et al.1 reported that there is no need for
histopathological analysis in patients <30 years of age as
significant pathology is uncommon in younger patients.
However, McEvoy29 et al. evaluated breast cancer risk in
women aged <35 years with ADH, ALH, and LCIS and
discovered that 12% developed breast cancer after a mean
of 7.5 years. They recommended close clinical follow-up.
Similarly, Hartmann et al.31 showed in the Mayo Clinic
cohort study that breast cancer risk is increased in young
women with atypia. Given the markedly increased risk of
breast cancer in women with ADH, ALH, and LCIS, sending
reduction mammaplasty specimens for histopathological
analysis also for women <40 years of age captures this
population for future surveillance.
In our study, there was a statistically significant differ-
ence in age and specimen weights between patients with
normal and abnormal histopathologies. Patients with
abnormal histopathology were older, and the specimens
were heavier. Other variables did not differ between these
groups. From these findings, it is difficult to set a certain
“cutoff” threshold for when to send specimens for histo-
pathological analysis. Recent studies28,31 have shown that
family history of breast cancer does not increase the risk of
breast cancer in patients with atypia beyond that of atypia
itself. This indicates that on the basis of demographics and
family history, histopathological analysis should not be
preoperatively ruled out.
Standard use of preoperative imaging before reduction
mammaplasty remains controversial as no consensus for
such criteria exists. In our study, the majority of the pa-
tients (81%) with abnormal findings in reduction mamma-
plasty specimens had normal preoperative imaging.
Similarly, others3,9e11,33 have noticed that incidental dis-
covery of atypical hyperplasias, in situ findings, or cancers
in reduction mammaplasty specimens are not associated
with abnormal preoperative mammograms. In our study,
preoperative diagnostics revealed only two high-risk lesions
(ADH and LCIS) and two cancers. Small invasive cancers,
DCIS, and high-risk lesions may remain undetected with
imaging, including MRI. Considering the low number of
preoperatively detected abnormal findings, our results
indicate that preoperative imaging does not sufficientlydetect high-risk or malignant findings. Therefore, histo-
pathological analysis of reduction mammaplasty specimens
seems difficult to bypass.
In our study, there were 69 (7.5%) patients with no
sample for histopathological analysis. Some surgeons based
their decision on the young age of the patients. However,
older patients were also present in this group (range 19e66
years). The reason for not sending older, e.g., >40 years,
patients’ samples for histopathological analysis remains
unclear. In addition, there were 12 patients with no pre-
operative imaging or histopathological analysis of reduction
mammaplasty specimen eliminating all pre- and post-
operative diagnostics.
Current risk management options for women with ADH,
ALH, or LCIS include active surveillance, chemoprevention,
and, more rarely, bilateral prophylactic
mastectomy.26,28e30,34 During the study period, mammo-
gram and ultrasound were recommended every 2 years for
the majority of these high-risk patients. The current sur-
veillance protocol in our unit for women <50 years includes
both mammogram and ultrasound annually. For women
between 50 and 69 years, mammogram is recommended
annually, and for women of >69 years, mammogram is
recommended every 2 years. Houssami et al.35 found no
difference in the sensitivity of screening mammogram for
breast cancer detection between women with ADH, ALH, or
LCIS and a control group lacking a history of these findings.
However, they stated that these patients may benefit from
adjunct (ultrasound or MRI) screening because of lower
mammogram specificity and higher interval cancer rates.
Berg et al.36 also stated that in women with increased risk
of breast cancer, supplementation of ultrasound resulted in
not only a higher rate of cancer detection but also an in-
crease in false-positive findings. For women <35 years of
age with ADH, ALH, and LCIS, McEvoy et al.29 recommended
MRI starting at 25e29 years of age and screening mammo-
grams for those >30 years. Thus, this supports that active
surveillance with tailored imaging is justified.
The use of chemoprevention for risk management has
been shown to reduce breast cancer incidence among
women with atypical hyperplasia and LCIS at 10 years from
21% to 8%.30 Similarly, King et al.28 showed a reduction in
breast cancer incidence at 10 years from 21% to 12% in
women with LCIS on chemoprevention compared to women
with no chemoprevention. Current guidelines by the
American Society of Clinical Oncology34 recommend the
discussion of tamoxifen as an option to reduce the risk of
breast cancer in pre- and postmenopausal women at
increased risk of breast cancer or with LCIS and the dis-
cussion of raloxifene and exemestane with postmenopausal
women. Morrow et al.26 concluded that substantial and
persistent elevation in breast cancer risk in these women is
sufficient to justify a discussion of chemoprevention with
those in good health, particularly premenopausal women.
To our knowledge, in our health care system, chemopre-
vention is barely ever offered to patients with increased
risk of breast cancer.
In our study, only two patients developed breast cancer
during the rather short follow-up period. Both cancers were
ipsilateral to the high-risk lesion. Hartmann et al.31 showed
that cancers developing within 5 years of diagnosis of atypia
were more likely to be ipsilateral than cancers arising later.
Should we routinely analyze reduction mammaplasty specimens? 201It has been reported that routine histopathological
analysis of reduction mammaplasty specimens is not cost-
effective because the incidence of occult cancers in the
specimens is low.1,37 However, as Kececi et al.18 suggested,
these figures are usually calculated for individual cancers
detected and do not consider risk-increasing findings. High-
risk lesions should be considered in determining whether
histopathological analysis of specimens is cost-effective or
not. The importance of high-risk lesions for the patients is
clear over time.18
There are some limitations to our study. Because of its
retrospective nature, we could not standardize preopera-
tive routines and histopathological sampling. Nevertheless,
this study cohort represents common plastic surgery prac-
tice. In this study, the follow-up time is short (mean
6.2  1.4 years), which probably affected the number of
subsequent cancers. With longer follow-up, more cancers
may be detected in these high-risk patients.
To conclude, preoperative diagnostics and demographics
do not sufficiently detect malignant or cancer risk-
increasing findings. Therefore, histopathological analysis
of reduction mammaplasty specimens seems mandatory.
Reduction mammaplasty combined with subsequent histo-
pathological examination offers a sufficient chance of
detecting cancer and risk-increasing lesions that merits the
cost of histopathology.
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